3,4 Nonetheless, lowering the IOP is considered the only proven intervention to decelerate disease progression. 1,2 High intraocular pressure (IOP) is one of the major risk factors for the development and progression of open-angle glaucoma (OAG) but is not an essential criterion for diagnosis. Glaucoma is a major cause of irreversible blindness worldwide. Hydrus, iStent, iStent inject, iStent infinite, minimally invasive glaucoma surgeries, trabecular microbypass Article: This articles reviews publications about all trabecular meshwork bypass stents, comparing them in terms of their efficacy and safety. The Hydrus ® Microstent (Ivantis Inc., Irvine, CA, US) is another trabecular implant that dilates and scaffolds Schlemm’s canal. The second-generation iStent inject ® (Glaukos Corp, Laguna Hills, CA, USA) is a smaller implant that allows simultaneous implantation of two stents, which could theoretically result in lower intraocular pressure. It allows aqueous humour to be drained directly from the anterior chamber to Schlemm’s canal, bypassing the trabecular meshwork, which is believed to be the main site of outflow resistance. The first-generation iStent ® (Glaukos Corp, Laguna Hills, CA, USA) is the first minimally invasive glaucoma surgery device to be approved for the treatment of open-angle glaucoma. Their target is to lower intraocular pressure with minimal eye trauma and fewer complications. Minimally invasive glaucoma surgery procedures are newly developed surgical modalities for the management of glaucoma.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |